53results about "Nucleic acid reduction" patented technology

The invention provides an engineered nuclease with high salt tolerance. The polypeptide comprises one or more mutations, so that the three-dimensional structure of the polypeptide has more surface areas with positive charges. Compared with the nuclease with the SEQ ID NO: 1 sequence, the polypeptide still has at least 60% nuclease activity under the condition that the solution ion strength exceeds 200 mM.

Disclosed herein, inter alia, are devices and methods for transfer and analysis of tissue sections using carrier substrates.

The invention provides a post-treatment method of single-cell protein fermentation liquor and a fermentation method of single-cell protein thalli. Nuclease and cell wall lytic enzyme are respectively added into fermentation liquor containing single-cell protein thalli to treat the thalli, so that nucleic acid and cell wall residues can be reduced, and the problems that in a traditional fermentation process, the application of the thalli in food is limited due to the high nucleic acid content of the thalli, and the protein extraction efficiency is reduced due to the existence of the cell walls are solved. In addition, by optimizing fermentation conditions, the protein content of the single-cell protein is remarkably increased. The process is simple, low in cost, suitable for industrial production and capable of being widely applied to the fields of feed, food and medicine.

Disclosed herein, inter alia, are devices and methods for transfer and analysis of tissue sections using carrier substrates.

The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

The present disclosure provides compositions for improved Rhizobium-mediated transformation in transformation of recalcitrant plants, and methods of use thereof. Also provided are compositions and methods for Rhizobium-dependent delivery of heterologous proteins directly to plant cells.

Disclosed herein is a non-chromosomal dynamic activity system (ADAS) derived from a parent bacterial cell comprising at least one loss of genetic function in a lyase to increase the stability of the ADAS. Also disclosed are methods of blocking sporogenesis in a parent bacterial cell in combination with a lyase deletion or other loss-of-function mutation.

The present application relates to protein derived from microorganisms, and more specifically derived from yeasts, that possess low RNA content and high gelling capacity. This application also relates to an industrial process and industrial uses of such single cell proteins for human and animal nutrition, health and well-being.

Provided is an engineered nuclease with high salt tolerance. The polypeptide comprises one or more mutations so that the polypeptide possesses more positive charged surface area in its three-dimensional structure. The polypeptide has at least 60% nuclease activity under a solution ionic strength more than 200 mM as compared to the nuclease having the sequence of SEQ ID NO: 1.

Provided herein are achromosomal dynamic active systems comprising a Type 1 pilus (TIP) and methods of making and using the same.

Provided is a method for nucleic acid reduction in a bacterium to less than about 5 wt % of a total dry weight of the bacterium, the method comprising culturing the cells of the at least one bacterium in a fermentation medium to obtain a fermentation medium comprising a biomass; heating the biomass to a temperature of at least 70° C. for at least 10 minutes; and washing the biomass. Also provided are food components, food ingredients and foods or beverages comprising single cell proteins produced from such bacteria.

The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

The disclosure provides for methods of constructing synthetic chromosomes including the steps of providing host cells with an endogenous chromosome, transforming a cloning vector and a cloning cassette into the host cells, excising target genomic nucleic acids from the endogenous chromosome, recombining the excised target genomic nucleic acids with the cloning cassette via homologous recombination to form heterologous vectors comprising cloned sequences, extracting the heterologous vectors containing the cloned sequences from the host cells, digesting the heterologous vectors with a restriction endonuclease to release the cloned sequences from the heterologous vectors to provide released cloned sequences, and introducing the released cloned sequences, a centromere cassette, and a yeast artificial chromosomes or bacterial artificial chromosomes into a second host cell, such that the released cloned sequences, the centromere cassette, and the YAC or BAC recombine with one another via homologous recombination to produce the synthetic chromosome.

The present application provides engineered nucleases with high salt tolerance. The polypeptides contain one or more mutations that increase the positively charged surface area in the three-dimensional structure of the polypeptide. The polypeptides have at least 60% of the nuclease activity at a solution ionic strength of greater than 200 mM compared to a nuclease having the sequence of SEQ ID NO:1.

The present invention relates to novel stable bacterial extract preparations having substantial increased stability overtime, novel methods of preparation thereof, pharmaceutical formulations based on these novel stabilized bacterial extracts, as well as novel routes of administration and delivery devices for treating and / or preventing acute and chronic immunological disorders resulting from infections and / or inflammation and / or neoplasms and / or dysbiosis.

Disclosed herein, inter alia, are compositions and methods for efficient transfer and analyses of cellular material, tissue samples, such as tissue sections, using carrier substrates.

Described herein is a modified bacterial strain lacking an insertion sequence (IS), wherein the modified bacterial strain (i) includes a specific deletion of an IS present in an unmodified bacterial strain, and (ii) retains non-IS sequences flanking the IS in the unmodified bacterial strain. There is also provided a method for producing said modified bacterial strains, the method comprising: (a) providing a bacterial strain comprising an IS flanked by non-IS sequences; and (b) specifically deleting the IS in the bacterial strain without deleting non-IS sequences flanking the IS.

The object of the present invention is to provide a decellularized graft which has any thickness and specific shape. The problem can be solved by a decellularized cellular structure of the present invention, which is a decellularized cultured cellular structure, characterized by having porosity ratio of 30% to 80%.

The present invention relates to novel stable bacterial extract preparations having substantial increased stability overtime, novel methods of preparation thereof, pharmaceutical formulations based on these novel stabilized bacterial extracts, as well as novel routes of administration and delivery devices for treating and / or preventing acute and chronic immunological disorders resulting from infections and / or inflammation and / or neoplasms and / or dysbiosis.

Disclosed herein is a non-chromosomal dynamic activation system (ADAS) derived from a parent bacterial cell, the ADAS comprising at least one genetic loss-of-function modification in a lytic enzyme to increase the stability of the ADAS. Also disclosed is a method for disrupting sporulation in the parent bacterial cell in combination with a lytic enzyme deletion or other loss-of-function mutation.

To provide an animal serum, mainly FBS, that does not contain RNA or contains a minimum amount of RNA, enabling research in cell cultures without risk of contamination or interference by the RNA of the serum.SOLUTION: The present invention relates to RNA-free mammal serums which can be useful for cell culture or for producing pharmaco-biological products due to the fact that they maintain their supplementation features. Another embodiment of the present invention relates to a method for removing RNA from mammal serum through the application of sequential serum heating, alkalization, and neutralization steps.SELECTED DRAWING: None

The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.

Disclosed herein is a non-chromosomal dynamic activation system (ADAS) derived from a parent bacterial cell that contains at least one loss-of-function genetic modification in a lytic enzyme to increase the stability of the ADAS and at least one gene loss-of-function in a protease to improve cargo expression, with or without an additional engineered cell wall-embedded anchor structure to optimize cargo presentation.

The invention relates to ApsA and ApsB proteins, including ApsA-like and ApsB-like proteins, and to their involvement in the mobilisation of the carbapenemase blaOXA-48 gene from the pOXA-48 plasmid into the chromosome. The ApsA and ApsB proteins combine a nuclease / helicase protein and a novel type of Argonaute-like protein to cleave DNA. The invention encompasses compositions comprising ApsA and ApsB proteins, including ApsA-like and ApsB- like proteins, antibodies against these proteins, nucleic acids encoding these proteins, vectors expressing these proteins and cells and kits comprising these nucleic acids, vectors and / or proteins. The invention further encompasses methods for making and using these compositions for diagnostic assays and for genetic engineering.

The present invention relates to novel stable bacterial extract preparations having substantial increased stability overtime, novel methods of preparation thereof, pharmaceutical formulations based on these novel stabilized bacterial extracts, as well as novel routes of administration and delivery devices for treating and / or preventing acute and chronic immunological disorders resulting from infections and / or inflammation and / or neoplasms and / or dysbiosis.

Method. The method includes providing a filter medium comprising a functionalized nonwoven fabric; passing a first fluid containing cells through the filter medium, where at least a portion of the cells are captured by the functionalized nonwoven fabric; passing a second fluid, and optionally a third and / or fourth fluid, through the filter medium, where the second and / or the third and / or the fourth fluid disrupts at least one of the captured cells; and recovering intracellular biological products in the first and / or the second and / or the third and / or the fourth fluid.

The present application relates to protein derived from microorganisms, and more specifically derived from yeasts, that possess low RNA content and high gelling capacity. This application also relates to an industrial process and industrial uses of such single cell proteins for human and animal nutrition, health and well-being.